AI-generated summary
The authors report a randomized, double-blind trial of 122 adults with nonseasonal major depressive disorder comparing bright light therapy, fluoxetine, their combination, and placebo over 8 weeks. Light monotherapy and the combination were associated with greater reductions in depression scores than placebo, while fluoxetine alone was not, with the combination showing the most consistent effects.
- Participants
- 122
- Who or what was studied
- Adults aged 19-60 years with nonseasonal major depressive disorder of at least moderate severity in outpatient psychiatry clinics at academic medical centers
- Limits stated in the abstract
- The abstract reports a modest sample of 29 to 32 patients per group and does not describe the trial as having a limitation beyond the small group sizes.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on archpsyc.jamanetwork.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Depression, Sham, Bright light therapy, Trial registration, Effect size, Lux. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.